As biopharma investors follow the latest buzz around advancements in clinical research, they may be under-appreciating opportunities in neurology, psychiatry and genetic medicine, according to a report from Oppenheimer. Specifically, analyst Jay Olson called out companies such as Biogen , Karuna Therapeutics and Crispr Therapeutics , among others. "Our analysis shows Genetic Medicine and Metabolic outperformed by > 20% on average over the ~5.
In July, the Food and Drug Administration could grant full approval to Leqembi , its Alzheimer's Disease treatment. That could then prompt the Centers for Medicare and Medicaid Services to agree to reimburse patients for the treatment, which could cost Medicare as much as $5 billion per year, a recent study published in JAMA Internal Medicine found .